DENND5B Gene Expression as a Trigger for the Development of Diabetes Mellitus-Peripheral Artery Disease: Insights from a Univariate and Multivariate Mendelian Randomization Study.
Qiaoqiao Li, Fuli Cao, Xueping Gao, Yuan Xu, Bo Li, Tianyang Hu
{"title":"DENND5B Gene Expression as a Trigger for the Development of Diabetes Mellitus-Peripheral Artery Disease: Insights from a Univariate and Multivariate Mendelian Randomization Study.","authors":"Qiaoqiao Li, Fuli Cao, Xueping Gao, Yuan Xu, Bo Li, Tianyang Hu","doi":"10.5334/gh.1373","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis that can result in limb pain, disability, or mortality. Notably, diabetes mellitus (DM) stands out as one of the most significant risk factors for the development of PAD. Compared to individuals with PAD but no DM, those with concurrent DM and PAD (DM-PAD, diabetes mellitus-peripheral artery disease) face a seven-fold higher risk of critical limb ischemia and a five-fold higher risk of amputation. However, the pathogenic factors and effective therapeutic targets for DM-PAD still remain elusive.</p><p><strong>Method: </strong>To identify candidate hub genes and develop insights into the pathogenesis of DM-PAD, we employed a comprehensive approach encompassing two-sample Mendelian Randomization (two-sample MR), summary data-based Mendelian randomization (SMR), and Bayesian colocalization (COLOC) methods. These methodologies facilitated the integration of summary-level data derived from genome-wide association studies of DM-PAD with expression quantitative trait locus (eQTLs) studies conducted on blood samples.</p><p><strong>Result: </strong><i>DENND5B, C4A</i>, and <i>CYP21A2</i> were found to have passed two-sample MR and SMR analyses, indicating their status as hub genes associated with DM-PAD through mechanisms involving not linkage but rather causality. The COLOC analysis provided strong evidence suggesting that <i>DENND5B</i> and the DM-PAD trait were influenced by the common causal variant rs1150948.</p><p><strong>Conclusion: </strong>Our study has pinpointed several crucial genes (<i>DENND5B, C4A</i>, and <i>CYP21A2</i>), notably the <i>DENND5B</i> gene, as potential regulators in the pathogenesis of DM-PAD. These discoveries hold promises for shedding light on the underlying mechanisms and novel targets of the disease in future research.</p>","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"19 1","pages":"91"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623097/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1373","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis that can result in limb pain, disability, or mortality. Notably, diabetes mellitus (DM) stands out as one of the most significant risk factors for the development of PAD. Compared to individuals with PAD but no DM, those with concurrent DM and PAD (DM-PAD, diabetes mellitus-peripheral artery disease) face a seven-fold higher risk of critical limb ischemia and a five-fold higher risk of amputation. However, the pathogenic factors and effective therapeutic targets for DM-PAD still remain elusive.
Method: To identify candidate hub genes and develop insights into the pathogenesis of DM-PAD, we employed a comprehensive approach encompassing two-sample Mendelian Randomization (two-sample MR), summary data-based Mendelian randomization (SMR), and Bayesian colocalization (COLOC) methods. These methodologies facilitated the integration of summary-level data derived from genome-wide association studies of DM-PAD with expression quantitative trait locus (eQTLs) studies conducted on blood samples.
Result: DENND5B, C4A, and CYP21A2 were found to have passed two-sample MR and SMR analyses, indicating their status as hub genes associated with DM-PAD through mechanisms involving not linkage but rather causality. The COLOC analysis provided strong evidence suggesting that DENND5B and the DM-PAD trait were influenced by the common causal variant rs1150948.
Conclusion: Our study has pinpointed several crucial genes (DENND5B, C4A, and CYP21A2), notably the DENND5B gene, as potential regulators in the pathogenesis of DM-PAD. These discoveries hold promises for shedding light on the underlying mechanisms and novel targets of the disease in future research.
Global HeartMedicine-Cardiology and Cardiovascular Medicine
CiteScore
5.70
自引率
5.40%
发文量
77
审稿时长
5 weeks
期刊介绍:
Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources.
Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention.
Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.